Kumar Ravindra 4
4 · ACCELERON PHARMA INC · Filed Sep 14, 2017
Insider Transaction Report
Form 4
Kumar Ravindra
VP & Chief Scientific Officer
Transactions
- Sale
Common Stock
2017-09-12$39.39/sh−500$19,695→ 90,222 total - Sale
Common Stock
2017-09-12$38.31/sh−4,605$176,418→ 90,722 total - Sale
Common Stock
2017-09-13$38.12/sh−8$305→ 90,214 total
Footnotes (3)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.81 to $38.70 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.88 to $39.82 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.